BREAKING NEWS

BioNTech to price coronavirus vaccine below market rates

By REUTERS

NOVEMBER 10, 2020 12:26

BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.

Speaking at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would reflect the financial risks that its private-sector investors have incurred.

"We’ve tried to pursue a balanced approach that recognizes that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we're in and with the goal to insure broad-based access around the world," Richardson said at the FT event.

"I expect there to be differential pricing in certain regions of the world," he added, declining to elaborate on the different price tags.

Children in Safed find Mandate-era grenade, sappers called to the scene

By ELI ASHKENAZI

11/25/2024 11:53 AM

Rocket fired from northern Gaza falls in open area

By JERUSALEM POST STAFF

11/25/2024 11:52 AM

Ukraine's air force says it downed 71 drones during Russia's attack

By REUTERS

11/25/2024 11:45 AM

Lebanon condemns recent attack on UNIFIL Italian contingent

By REUTERS